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ABSTRACT
Members of the protein kinase family are amongst
the most commonly mutated genes in human
cancer, and both mutated and activated protein
kinases have proved to be tractable targets for
the development of new anticancer therapies
The MoKCa database (Mutations of Kinases in
Cancer, http://strubiol.icr.ac.uk/extra/mokca) has
been developed to structurally and functionally
annotate, and where possible predict, the pheno-
typic consequences of mutations in protein kinases
implicated in cancer. Somatic mutation data from
tumours and tumour cell lines have been mapped
onto the crystal structures of the affected protein
domains. Positions of the mutated amino-acids are
highlighted on a sequence-based domain picto-
gram, as well as a 3D-image of the protein structure,
and in a molecular graphics package, integrated for
interactive viewing. The data associated with each
mutation is presented in the Web interface, along
with expert annotation of the detailed molecular
functional implications of the mutation. Proteins
are linked to functional annotation resources and
are annotated with structural and functional features
such as domains and phosphorylation sites. MoKCa
aims to provide assessments available frommultiple
sources and algorithms for each potential cancer-
associated mutation, and present these together
in a consistent and coherent fashion to facilitate
authoritative annotation by cancer biologists and
structural biologists, directly involved in the genera-
tion and analysis of new mutational data.
INTRODUCTION
Cancers arise due to the accumulation of mutations in
critical target genes that confer a selective advantage on
the cell (and its progeny) that contain them. Knowledge
of these mutations is key to understanding the biology of
cancer initiation and progression, as well as to the devel-
opment of more targeted therapeutic strategies. While
there are rare examples of cancers driven by a single
genetic alteration (1), in most solid tumours, tumourigen-
esis is a multistep process (2,3), reﬂecting the genetic
alterations necessary to transform normal cells into malig-
nant derivatives. The crucial events include acquisition
of genomic instability, cell cycle deregulation, evasion of
apoptosis, limitless replicative potential, angiogenesis and
metastasis (4). Regardless of the multiple mutations ulti-
mately required, a single mutation can initiate the process.
Members of the protein kinase family are amongst the
most commonly mutated genes in human cancer, and both
mutated and activated protein kinases have proved to be
tractable targets for the development of new anticancer
therapies (5). There are 518 documented mammalian
protein kinases (6) encoded in the human genome, which
together represent the largest family of human enzymes,
collectively termed the kinome. They play indispens-
able roles in numerous cellular, metabolic and signalling
pathways, in all cell types. Around 40% of the kinome
have multiple splice variants and 10% of the total encode
catalytically deﬁcient enzymes that have been termed
pseudokinases.
Although there are several kinase classiﬁcation schemes
(e.g. 6,7), the KinBase resource (http://www.kinase.com/
kinbase) (6) reﬂects the currently accepted classiﬁcation of
eukaryotic protein kinases where the kinases are broadly
split into two groups: conventional protein kinases (ePKs)
and atypical protein kinases (aPKs). The ePKs are the
largest group, and are subclassiﬁed into eight families
using the sequence similarity of the kinase domain, the
presence of accessory domains, and consideration of
their modes of regulation. The aPKs are a smaller set of
protein kinases that do not share clear sequence similar-
ity with ePKs, but have been shown experimentally to
have protein kinase activity. As the entries in KinBase
are ﬁltered by stringent criteria, including veriﬁcation by
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cDNA cloning, the KinBase classiﬁcation scheme is the
one favoured by experimentalists working on kinases
and signal transduction pathways.
Protein kinases are frequently found to be mis-regulated
in human cancer, and the Cancer Genome Project and sim-
ilar initiatives, have undertaken systematic re-sequencing
screens of all annotated protein kinases in the human
genome, to attempt to identify commonly occurring muta-
tions that may play signiﬁcant roles in a range of diﬀer-
ent cancers (8–10). In all cases the key to understanding
the contribution of a particular disease-associated kinase
mutation to development and progression of cancer, comes
from an appreciation of the consequences of that muta-
tion on the function of the aﬀected protein, and the
impact on the pathways in which that protein is involved.
It is this that the MoKCa database described here, aims
to facilitate.
Changes in the nucleotide sequence of a gene can have a
variety of consequences for the encoded protein, including
truncations and frameshifts that disrupt the protein struc-
ture and/or reduce transcript levels via nonsense-mediated
RNA decay. The most common mutational event is a
single base change, leading to a missense mutation of a
single amino acid. Cancer-associated somatic mutations
(CASMs) or missense variants are commonly identiﬁed
in somatic tumour DNA, but only a fraction directly
contribute to oncogenesis. Distinguishing those that con-
tribute to cancer from those that do not is a diﬃcult pro-
blem, potentially requiring detailed and protracted
functional analysis. However the ability to make this
determination, both rapidly and inexpensively, will be
essential to realization of ‘personalized therapy’ targeted
to the individual tumour.
Several approaches have been taken to predict which
genes contain mutations that contribute to mutagenesis
(i.e. drivers genes) rather than those genes that contain
mutations that arise by chance but have no bearing on
the disease (passenger mutations). Statistical models com-
paring the observed ratio of non-synonymous:synon-
ymous compared with that expected by chance, have
been used to identify and estimate the number of cancer
drivers within a total set of identiﬁed genetic variation
(11). These methods are excellent for predicting which
genes contain drivers, but do not identify the driver muta-
tion alone. Consequently algorithms have been developed
that attempt to assess the driver status of missense
mutations (12–14) based on the notion that evolutionary
conserved sites in a protein tend to be involved in its
function, and that mutations that change the properties
of these sites, alter that function. However the mechanistic
nature of a functional change (activation, inhibition or
subversion) and its detailed biochemical eﬀect, is virtually
impossible to predict without a detailed analysis of the
protein, informed by ‘expert’ insight into its individual
biology.
There are several protein family-speciﬁc databases that
collate disease-associated mutations from the literature,
such as SH2base (15) that contains data for germline
mutations in proteins containing SH2 domains, and
KinMutBase (16) which documents disease-related germ-
line mutations in 33 kinases. These data either derive from
repetitious sequencing in aﬀected families of particular
kinases mutated in speciﬁc diseases, or from harvesting
literature identiﬁcations of mutations observed in individ-
ual studies. Furthermore, the COSMIC database (17), is
undertaking to document all somatic cancer mutations
reported in the literature.
By bringing together automatic assessments available
from multiple sources and algorithms for each potential
cancer-associated mutation, and presenting these in a con-
venient and coherent fashion, MoKCa aims to facilitate
authoritative annotation by cancer biologists and struc-
tural biologists, directly involved in the generation and
analysis of new mutational data. These ‘experts’ are then
able to bring detailed insights into the biochemistry and
biology of individual proteins and systems, that are vir-
tually impossible to encapsulate in an algorithm, but are
key to determining if and how a particular mutation will
alter the biological function of a protein. Thus the MoKCa
database combines automated and ‘expert’ annotation of
individual mutations, and is ﬁrmly directed towards the
speciﬁc needs of the cancer research community.
BUILDING THE MoKCa DATABASE
Mutation data
The original mutational data was provided by the Sanger
Cancer Genome Project (CGP) Team, and comprises
the mutations found in the large-scale re-sequencing of
the kinase complement from 210 human cancers. This
included samples from breast, lung, colorectal, gastric,
testis, ovarian, renal, melanoma, glioma and acute lym-
phoblastic leukaemia (ALL) cancers (9). Of the 210
tumours studied, 169 were primary tumours, 2 were
early cultures and 39 immortal cell lines.
One-thousand and seven somatic mutations are docu-
mented in the coding exons and splice junctions in the
kinases of 137 of the tumours studied. Nine-hundred and
twenty one were single base substitutions, 78 were small
insertions or deletions and 8 were complex changes. Of the
single base substitutions, 620 were missense changes, 54
caused nonsense changes and 28 were observed at highly
conserved positions of splice junctions. There were also
219 silent (synonymous mutations). Approximately one-
third of these mutations had previously been reported in
the literature.
Added to this core dataset, are additional somatic
mutational data from the COSMIC database that have
been curated from the literature (17). This includes
15 911 missense, 47 nonsense and 50 insertions or dele-
tions. This results in a non-redundant mutation dataset
of 1406 distinct mutations from over 20 diﬀerent types
of cancer: 269 silent, 912 missense, 83 nonsense, 27
splice site, 84 deletions and 8 multi substitutions.
Driver/passenger assignment of a gene
The Sanger kinase study is by far the largest dataset relat-
ing to somatic kinase mutations, and has the advantage of
generating a clear picture of the background mutational
levels in each gene and in each tumour. This allows the
estimation of the likelihood of mutations in a particular
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gene being signiﬁcant as a driver of each particular
tumour. The deviation of the ratio of non-synonymous:-
synonymous mutations from that expected by chance, was
used to indicate the presence of selection in genes on non-
synonymous mutations.
Each gene is assigned the selective pressure calculated
by Greenman et al. (11): Of the 921 base substitutions in
the primary screen 763 are estimated to be passenger
mutations, with an estimated 158 driver mutations pre-
dicted to be distributed within 119 genes. Each gene is
also assigned a rank, which reﬂects the probability of
the gene containing at least one driver mutation.
Data normalization and domain assignment
The translated CGP kinase nucleotide sequences were
used as reference sequences, and were scanned against
Swiss-Prot/TrEMBL (18) using BLASTP (19), to identify
the corresponding Swiss-Prot protein entry, which was
then used for numbering, annotation and linking to other
major primary and secondary databases. Kinase sequences
were mapped to the closest Swiss-Prot sequence and the
alignments stored in the database—where more than one
isoform was identiﬁed the longest transcript was adopted
as the matched sequence. This protocol was repeated for
the reference sequences from the COSMIC database.
Kinase classiﬁcation schema were extracted from
KinBase, and each kinase assigned to its group, family
and sub-family. Alternative Gene identiﬁers were extracted
from KinBase and Swiss-Prot and stored in a pseudonym
table. Gene names were also mapped to HUGO identiﬁers
(20). Domain boundaries were extracted from Pfam (21),
and both PfamA and PfamB domains are displayed.
PROSITE patterns (22) are used to identify kinase signa-
ture patterns, for example the Serine/Threonine protein
kinases active-site signature and Protein kinases ATP-
binding region signature. Known phosphorylation sites
were downloaded from Phospho.ELM (23) and mapped
on to the kinase sequences to help determine whether a
mutation changes a residue normally post-translationally
modiﬁed during its functional life.
Structural mapping of mutations
To map mutational data to protein structures, the
sequence for each Pfam domain or non-domain region
that contained a missense mutation, was scanned against
a database containing non-redundant protein sequences
(UniRef90) (18) and the sequences from the PDB using
PSI-BLAST (cut-oﬀ value of 10–4) (19). The kinase refer-
ence sequences and PDB sequences were then aligned.
To identify which mutations mapped onto residues
with structural density in the PDB ﬁle, PDB sequence to
structure alignments from the Structure integration with
function, taxonomy and sequence (SIFTS) initiative (24)
were utilized. Models of the structures with the substituted
residues are currently being generated and will be avail-
able shortly.
Automated assessment of pathogenicity of mutations
Prediction of which missense mutations contribute
to oncogenesis, are provided by the CanPredict
algorithm (12), which incorporates three independent
scoring schemes based on SIFT (25), Pfam logR.E (26)
and GOSS scores. The SIFT algorithm uses similarity
between closely related proteins to identify potentially
deleterious changes. SIFT scores <0.05 are predicted to
be deleterious. The Pfam-based logR.E-value score pre-
dicts whether a change will alter protein function by deter-
mining the diﬀerence in ﬁt of a wild-type version of the
protein to a particular Pfam model and a score >0.5 indi-
cates a deleterious change. Lastly, a GOSS metric uses the
gene ontology to measure the similarity of the function of
a gene to other known cancer-causing genes.
Protein–protein interaction data
Key to determining the impact of a mutation on the cell, is
the impact of the mutation on the proteins interactions
and pathways. Towards this goal, protein–protein interac-
tion data, for each kinase are provided by the ROCK
database (Zvelebil et al., unpublished), an Oracle-based
data warehouse that integrates a large number of experi-
mental and derived data in a modular design. ROCK will
provide a single online interface for the management,
navigation, cross-linking and cross-correlation of data
relating to breast cancer research from a wide variety of
laboratory and clinical studies. The core of the database
contains genomic and protein interaction datasets which
are linked to experimental results. Interaction datasets are
from MINT (27), MIPS (28), Reactome (29), BioGRID
(30), HPRD (31), IntAct (32), BIND (33) and derived
from Inparanoid (34) and Homologene (35) along with
data curated from literature (Supplementary Table 1).
Database design
MoCKa was implemented using a MySQL database run-
ning on a Linux server, with PERL scripts used for all
data retrieval and output. Its modular design is compati-
ble with future expansion and connectivity, and currently
contains the following subsections: Gene [EntrezGene
(35), RefSeq (35), Ensembl (36)], Pseudonyms, Protein
(Swiss-Prot/UniProt). Gene Ontology (37), Structure
(PDB) (38), Mutational data [CGP, COSMIC (17)],
Domain Structure and annotation [CATH (39), Gene3D
(40), Pfam (21), SMART (41)], Functional annotation
[Phospho.ELM (19)], Cancer data [Sequence, Mutations,
Cell line, Cancer sub-type, Selective Pressure (9)] and pro-
tein interactions for each kinase (ROCK).
THE MoKCa WEB-INTERFACE
At the highest level MoKCa provides the full list of 518
human protein kinases listed alphabetically by gene name
to facilitate browsing, with each entry labelled with the
number of mutations found, the cancer driver selection
pressure and rank, and an iconic representation of the
tumour type(s) in which mutations in that protein kinase
have been found. A ‘lightbulb’ icon indicates those pro-
teins for which expert annotations have been added. In
addition to alphabetic sorting on the gene name, the list
can be sorted by selective pressure or driver ranking
(Figure 1). Sorting on selective pressure is particularly
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informative in presenting those kinases that were found to
have the highest involvement in driving cancer in the study
of Greenman et al. (11), and probably presents the least
biased assessment of driver probability currently avail-
able. Alternatively, a ﬁltered list can be generated by ﬂex-
ible text-matching against gene name, UniProt accession
code, UniProt protein names and synonyms, or GenBank
ID. Future developments will allow selection of sub-sets of
genes based on attributes such as kinome ‘branch’ or asso-
ciation with speciﬁc tumour type(s). Website navigation is
assisted by a ‘breadcrumb’ system that tracks the user’s
journey through the database and allows them to return to
any stage.
Gene level
Selection of a gene from the full or ﬁltered list transfers the
user to a gene-level page, which provides information and
links relevant to the gene, its encoded protein and the
spectrum of mutations present in the database for that
gene. The encoded protein structure is represented as a
domain pictogram, with the positions of silent, missense,
nonsense, indel and frameshift mutations indicated.
Phosphorylation sites and other functional features are
also indicated (Figure 2a and b). A 3D-cartoon image of
the crystal structure most closely homologous to the
encoded protein and to which the greatest number of
mutations can be mapped, is shown, with the mapped
positions of mutated residues highlighted (see later).
Hyperlinks are provided to entries for the gene in the
Cancer Genome Project COSMIC database, SwissProt/
UNIPROT and the iHop literature browser (42).
Biological function can be accessed via a link to GO and
network interactions involving the encoded protein can be
explored via a link to ROCK.
The list of individual mutations identiﬁed for the gene,
annotated by the amino acid change, Pfam domain to
which they map, cancer driver prediction from
CanPredict (‘tick’ for probably cancer; ‘cross’ for prob-
ably not) and tumour type(s) in which they occur, provide
hyperlinks to the mutation level. The Pfam domain names
(for Pfam-A only) hyperlink to the functional deﬁnitions
for that domain. A ‘lightbulb’ icon indicates those muta-
tions for which expert annotations have been added.
Mutation level
The mutation-level pages provide information and links
relevant to the particular mutation, including details of the
tumour sample and type in which it was found, and the
breakdown of the CanPredict assessment of the cancer
probability of that mutation, where available. SMART
and Pfam domain boundary mappings on to the amino
acid sequence are also provided. A hyperlinked list is pro-
vided of all Protein Databank 3D structures (ranked by
sequence identity) that match the amino acid sequence of
the aﬀected domain with a signiﬁcant PSI-BLAST e-value.
The list is sorted by sequence identity with each entry
annotated with the BLAST e-value for the match, and
the protein chain and residue number in the structure
ﬁle that corresponds to the mutated residue. A 3D-cartoon
image is generated of the highest homology structure in
which the equivalent to the aﬀected residue was structu-
rally deﬁned, with that residue highlighted. Hyperlinks are
provided to launch an interactive session with the Jmol
viewing applet (http://www.jmol.org), in which the struc-
ture can be examined in 3D, and a script for the fully
Figure 1. MoKCa kinase gene list. Genes encoding protein kinases are shown listed by ranking of their probability of containing one or more cancer-
driving mutation (11). Gene names are additionally annotated with number of mutations found in the Cancer Genome Project analysis (9), the
calculated selection pressure on that gene, and indicators showing the cancer types in which the gene was found mutated. The list can also be sorted
alphabetically or by selective pressure. Gene names hyperlink to gene-level pages.
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featured molecular Graphics program PyMol (http://
www.pymol.org) can be downloaded.
Registered ‘expert’ users are able to access text ﬁelds in
which they can enter their expert assessment of the
mechanistic eﬀect of the particular mutation based on
the automated predictions and detailed examination of
the structural mapping. The mechanism describes the
change in biological activity that results from the mutation
and includes whether the kinase activity increases or
decreases, and whether this results in a tumour suppressor
or oncogenic eﬀect on the cell or its pathways. Whereas
the evidence refers to the publications in which the pro-
posed mechanism has been described. It can be direct or
inferred from a similar mutation in a homologous protein
or in an analogous system.
These opinions are visible on the mutation-level pages,
but not editable, by other users. Future developments will
include hyperlinked bibliographic references in support of
the expert opinion.
Protein functional interaction networks
Interaction maps are displayed using ROCKscape
with nodes representing proteins and edges represent-
ing interaction or transcriptional regulatory relationships
between components. Depending on the respective display
mode selected, edges are colour-coded to identify the type
of interaction, and nodes are coloured with selective pres-
sure. Interaction maps can also be progressively expanded
outwards to display the next interaction neighbourhood
or subsequent levels beyond, thus, making it possible to
‘grow’ networks or extend signalling pathway modules in
a desired direction.
EXAMPLE OF USE
One of the ﬁrst discoveries of the Cancer Genome Project
was that mutations in BRAF were found in 70% of mel-
anomas, and to a lesser extent in colorectal, lung and
ovarian cancers. By browsing the MOKCA interface,
and choosing ‘selective pressure’, it is clear the BRAF is
near the top of the predicted driver list (Figure 1), and it
can be easily identiﬁed in which tumour types the muta-
tions arise. By following the link to the protein page it is
clearly visible that the mutations are all missense
(Figures 2c and 3a), are localized to the kinase domain,
and most are predicted to be pathogenic by CanPredict.
The illustration of the protein structure clearly shows that
the mutations are all tightly clustered in the 3D structure,
Figure 2. Mapping mutations to domains. The spectrum of mutations identiﬁed for each gene is shown on its gene-level page mapped on to a
schematic representation of the domain structure of the encoded protein. (a) The domain structure of each encoded protein (deﬁned by Pfam
deﬁnitions) is shown as a pictogram, with the positions of mutations annotated with icons speciﬁc to the type of mutation—silent, missense, nonsense
(stop), deletion (frameshift or in-frame) or insertion (frameshift or in-frame). Functionally important sequence features, such as documented
phosphorylation sites from Phospho.ELM (23) are also shown. Annotation of features such as active sites and ATP-binding motifs (from
Prosite) will be added in future versions. (b) Example domain pictogram for TGFBR2, showing missense mutations distributed in the extra-cellular
and kinase domains, a frameshift (probably truncating) deletion mutation in the extra-cellular domain, and a truncating nonsense mutation in the
C-terminal lobe of the kinase domain. Automated assessment by CanPredict identiﬁes a lung-cancer associated H328Y mutation as a cancer driver.
(c) Domain pictogram for BRAF, identiﬁed as a strongly selected mutated gene in melanoma and a range of other cancers, showing the cluster of
activating missense mutations in the activation segment.
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Figure 3. Mutations, mechanisms and pathways. (a) Gene-level pages (illustrated for BRAF) provide links to data for the gene in a range of primary
and other databases including COSMIC, UNIPROT and KinBase. Additional links are provided to GO functional annotations, Pfam deﬁnitions for
domains of the encoded protein, and Prosite motifs matched in the encoded protein sequence. A hyperlink to the ROCK Online Cancer Knowledge
base (Zvelebil et al., unpublished), provides view of the protein–protein interactions [see (c)]. A hyperlinked list of mutations, annotated with tumour
sample registry numbers, and indicators for tumour type and CanPredict assessment of driver probability, points out to individual mutation-level
pages [see (b)]. (b) Mutation-level pages give speciﬁc domain assignments and CanPredict assessments for the individual mutation, as well as
hyperlinks to a homology-ranked list of protein structures homologous to the aﬀected domain. A 3D-graphic overview of the domain is provided
with the mutated residue highlighted, and a Jmol session allowing interaction with the protein can be launched. ‘Expert’ users are able to enter a
description of the mechanistic implications of the particular mutation, if any, and evidence for that opinion. Future developments will include
bibliographic hyperlinks to relevant publications. (c) ROCK provides a graphical view (with optional Cytoscape viewer) of the documented protein–
protein interactions for the aﬀected gene (highlighted red). For other kinases appearing in the interaction network, the selective pressure for cancer-
associated mutations is used to colour the node. In the BRAF example shown, the two ERK kinases (MAP2K1/2) downstream of BRAF display no
selective pressure, whereas RAF1 (aka C-RAF) which co-operates in parallel with BRAF, displays a selective pressure for cancer driver mutations.
The displayed network can be interactively expanded or contracted, and interrogated, as required. A full description of ROCK will be presented
elsewhere.
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in and around the activation segment and phosphate-
binding loop.
Moving to the mutation pages, an annotated mechan-
ism for each mutation is described (Figure 3b). For
instance, Val 600, which is mutated to glutamate in several
diﬀerent melanomas as well as in ovarian and colorectal
tumours, lies at the beginning of the activation segment.
The V600E mutation destabilizes the auto-inhibited state
of the kinase, leading to constitutive kinase activity in the
absence of upstream activating signals. This provides the
tumours with self-suﬃciency in growth signals, one of
the key ‘hallmark’ traits of cancer (4) via its activation
of the downstream MAP kinase signalling pathway.
Following a hyperlink to the protein–protein interac-
tion page provided by ROCK (Figure 3c), the functional
interaction of BRAF with its downstream kinase phos-
phorylation targets ERK1/2 (MAP2K1/2) are evident.
Unlike the upstream BRAF, neither of these were found
to be under selective pressure for mutation in the tumours
analysed. It can also be seen that BRAF interacts with
RAF1, a known kinase proto-oncogene that also phos-
phorylates ERK1/2, and like BRAF is also under muta-
tional selective pressure.
DISCUSSION
MoKCa provides data and assessments from multiple
sources and algorithms for each potential cancer-
associated mutation, and the interactive display of the
data facilitates authoritative annotation by cancer biolog-
ists and structural biologists. These ‘experts’ will bring
detailed insights into the biochemistry and biology of indi-
vidual proteins and systems, that are virtually impossible
to encapsulate in an algorithm, but are key to determining
if and how a particular mutation will alter the biological
function of protein. Thus the MoKCa database combines
automated and ‘expert’ annotation of individual muta-
tions, and is ﬁrmly directed towards the speciﬁc needs of
the cancer research community.
FUTURE DEVELOPMENTS
As the various cancer genome and re-sequencing projects
continue to generate mutational data, these will be incor-
porated into the database. We also propose to add cancer-
related germline mutational data from OMIM, and
family-speciﬁc mutational databases such as SH2base
(15) and KinMutBase (16), which document inherited
genetic disease mutations.
The MoKCa database has been designed to combine
functional and protein-interaction data, with a user-
friendly interface to assess which kinases are most causal
of cancer, and which mutations are cancer drivers. It will
be important to be able to mine this information to predict
which mutated kinases will be eﬀective drug-targets.
The database will also be extended to include pathway
information, for both known and in-house pathways.
For fully documented pathways we will try to ascertain
at the molecular level, what aﬀect a mutation will have on
pathway function and how it aﬀects the ‘sign’ (activatory
or inhibitory) of the pathway interactions made by the
aﬀected protein.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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